Drug Modeling Software Market
Drug Modeling Software Market Forecasts to 2030 - Global Analysis By Component (Software and Database), By Deployment (Cloud Based, Hybrid-Based and On-Premises), Operating System (Windows, Linux, Mac Os and Other Operating Systems), Enterprise Size, Purchasing Model, Application, End User and By Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $7.7 BN |
|
Projected Year Value (2030) |
US $15.5 BN |
|
CAGR (2023-2030) |
10.5% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Drug Modeling Software Market is accounted for $7.7 billion in 2023 and is expected to reach $15.5 billion by 2030 growing at a CAGR of 10.5% during the forecast period Drug Modeling Software refers to computational tools employing algorithms and simulations to predict, analyze and optimize aspects of drug discovery and development. These programs facilitate the understanding of molecular interactions, pharmacokinetics and drug-target interactions. By simulating and modeling biological systems, chemical structures and drug behavior, they aid in designing, screening and optimizing potential drug candidates, enhancing the efficiency and success rates of pharmaceutical research and development processes.
According to the Pharmaceutical Research and Manufacturers of America, a successful drug's research and development cost an average of US$2.6 BN.
Market Dynamics:
Driver:
Growing need for novel treatments
With an increasing prevalence of complex diseases and evolving therapeutic requirements, there's a pressing need for innovative and effective treatments. Drug modeling software enables the exploration of diverse molecular structures and predictive simulations, expediting the identification and optimization of potential drug candidates. This technology-driven approach not only accelerates the discovery process but also aids in designing tailored therapies, meeting the demand for more precise, targeted and efficacious treatments, consequently propelling the software's significance and adoption in advancing healthcare innovation.
Restraint:
Validation and precision challenges
Ensuring the accuracy and reliability of predictive models requires extensive validation against experimental data, often demanding substantial time and resources. Additionally, complex biological systems and the diverse interactions between drugs and targets contribute to precision challenges, impacting the software's predictive capabilities. The limitations of accurately replicating real-world complexities hinder the software's effectiveness, necessitating continuous refinement and validation efforts.
Opportunity:
Rising interest in cloud-based analytics and data processing
Cloud platforms offer scalable, cost-effective infrastructure capable of handling vast datasets and complex computations. This shift allows for enhanced collaboration, faster processing speeds and greater accessibility to sophisticated modeling tools. Moreover, cloud-based solutions facilitate seamless integration with other applications and enable real-time data sharing among researchers globally. Embracing this trend not only streamlines workflows but also fosters innovation, empowering organizations to leverage cutting-edge technologies and drive advancements in drug discovery and development while optimizing costs and resource utilization.
Threat:
Data privacy and security concerns ?
Data privacy and security concerns pose a significant threat to the drug modeling software market. The sensitive nature of patient data and proprietary information in drug development raises apprehensions about potential breaches, unauthorized access or data misuse. Instances of security lapses could erode trust, impact adoption rates, and hinder collaboration between pharmaceutical entities and software providers. Moreover, stringent regulations like GDPR and HIPAA impose rigorous standards for handling healthcare data, augmenting the pressure on software developers to ensure compliance.
Covid-19 Impact:
The COVID-19 pandemic accelerated the adoption of drug modeling software, intensifying its role in remote drug development and virtual clinical trials. It prompted a heightened reliance on predictive analytics and computational methods for rapid drug design and repurposing, facilitating faster responses to emerging health crises. However, disruptions in research and clinical activities temporarily affected market growth. Yet, the pandemic underscored the software's criticality, spurring innovation and reinforcing its pivotal role in agile and remote drug development processes.
The hospitals & healthcare providers segment is expected to be the largest during the forecast period
The hospitals and healthcare providers segment is anticipated to lead the drug modeling software market due to its increasing leverage of advanced software for personalized treatment strategies, drug efficacy predictions and treatment optimization. With a focus on precision medicine, hospitals and healthcare providers utilize drug modeling software for clinical decision support, enhancing patient care outcomes. Additionally, the integration of these tools into electronic health records facilitates seamless implementation, contributing to the segment's dominance.
The drug discovery and development segment is expected to have the highest CAGR during the forecast period
The drug discovery and development segment is poised for significant growth owing to the continuous surge in demand for novel therapeutics. Drug developers increasingly rely on advanced modeling software to expedite the identification, design and optimization of potential drug candidates. Additionally, the integration of artificial intelligence and machine learning further enhances efficiency, driving the substantial anticipated growth of this segment within the drug modeling software market.
Region with largest share:
North America is anticipated to lead the drug modeling software market due to its robust pharmaceutical and biotech sectors. The region boasts significant R&D investments, advanced healthcare infrastructure and a strong presence of major industry players. Moreover, the region's emphasis on innovation and technology adoption, coupled with a high demand for personalized medicine and precision drug development, drives the use of sophisticated modeling software. These factors, combined with supportive regulatory frameworks and a culture of early adoption of novel technologies, position North America to dominate the drug modeling software market.
Region with highest CAGR:
Asia Pacific is poised for substantial growth in the drug modeling software market due to the region's burgeoning pharmaceutical and biotech industries, coupled with increasing R&D investments. Additionally, the presence of a vast patient pool for clinical trials and a growing emphasis on precision medicine foster the adoption of drug modeling software. Moreover, expanding healthcare infrastructure, technological advancements and supportive government initiatives propel growth in this region.
Key players in the market
Some of the key players in drug modeling software market include Acellera, Biovia, Certara, Chemical Computing Group, Collaborative Drug Discovery, Inc., Cresset, Genedata AG, Insilico Medicine, Instinctools GmbH, Leadscope, Inc., Molecular Networks GmbH, Nimbus Therapeutics, Numerate, Inc., OpenEye Scientific Software, Optibrium Ltd., Pharmacelera, Physiomics plc, Schrödinger, Inc. and Simulations Plus, Inc.
Key Developments:
In May 2023, Cresset announced the latest release of molecular modeling platform that delivers improved efficiencies for small molecule discovery therefore Flare V7. This helps the organisation developing more revenue.
In May 2023, Fujitsu launched the Biodrug Design Accelerator platform to increase peptide drug discovery research. This platform helps peptide drug discovery scientists in pharmaceutical industries to speed up and increases the efficiency of peptide drug development, especially through the cycles “design, make, test, analyze” (DMTA), ultimately allowing faster and informed design of peptide drug candidates and effective communication among scientists about synthesis and testing.
In February 2023, Accenture has made a strategic investment, through Accenture Ventures, in Ocean Genomics, a technology and AI company that has developed advanced computational platforms to assist biopharma companies to discover and develop more effective diagnostics and therapeutics.
Components Covered:
• Software
• Database
Deployments Covered:
• Cloud Based
• Hybrid-Based
• On-Premises
Operating Systems Covered:
• Windows
• Linux
• Mac Os
• Other Operating Systems
Enterprise Sizes Covered:
• Large Enterprise Size
• Small & Medium Enterprise Size
Purchasing Models Covered:
• Subscription Based
• One-Time License
Applications Covered:
• Cellular Simulation
• Cheminformatics
• Disease Modeling
• Drug Discovery and Development
• Gene Sequence Analysis
• Graphical Molecular Modeling
• Medical Imaging
• Protein Modeling
• Other Applications
End Users Covered:
• Contract Research Organizations (CROs)
• Pharmaceutical & Biotechnology Companies
• Hospitals & Healthcare Providers
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Drug Modeling Software Market, By Component
5.1 Introduction
5.2 Software
5.3 Database
6 Global Drug Modeling Software Market, By Deployment
6.1 Introduction
6.2 Cloud Based
6.3 Hybrid-Based
6.4 On-Premises
7 Global Drug Modeling Software Market, By Operating System
7.1 Introduction
7.2 Windows
7.3 Linux
7.4 Mac Os
7.5 Other Operating Systems
8 Global Drug Modeling Software Market, By Enterprise Size
8.1 Introduction
8.2 Large Enterprise Size
8.3 Small & Medium Enterprise Size
9 Global Drug Modeling Software Market, By Purchasing Model
9.1 Introduction
9.2 Subscription Based
9.3 One-Time License
10 Global Drug Modeling Software Market, By Application
10.1 Introduction
10.2 Cellular Simulation
10.3 Cheminformatics
10.4 Disease Modeling
10.5 Drug Discovery and Development
10.6 Gene Sequence Analysis
10.7 Graphical Molecular Modeling
10.8 Medical Imaging
10.9 Protein Modeling
10.10 Other Applications
11 Global Drug Modeling Software Market, By End User
11.1 Introduction
11.2 Contract Research Organizations (CROs)
11.3 Pharmaceutical & Biotechnology Companies
11.4 Hospitals & Healthcare Providers
11.5 Other End Users
10 Global Drug Modeling Software Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Acellera
12.2 Biovia
12.3 Certara
12.4 Chemical Computing Group
12.5 Collaborative Drug Discovery, Inc.
12.6 Cresset
12.7 Genedata AG
12.8 Insilico Medicine
12.9 Instinctools GmbH
12.10 Leadscope, Inc.
12.11 Molecular Networks GmbH
12.12 Nimbus Therapeutics
12.13 Numerate, Inc.
12.14 OpenEye Scientific Software
12.15 Optibrium Ltd.
12.16 Pharmacelera
12.17 Physiomics plc
12.18 Schrödinger, Inc.
12.19 Simulations Plus, Inc.
List of Tables
1 Global Drug Modeling Software Market Outlook, By Region (2021-2030) ($MN)
2 Global Drug Modeling Software Market Outlook, By Component (2021-2030) ($MN)
3 Global Drug Modeling Software Market Outlook, By Software (2021-2030) ($MN)
4 Global Drug Modeling Software Market Outlook, By Database (2021-2030) ($MN)
5 Global Drug Modeling Software Market Outlook, By Deployment (2021-2030) ($MN)
6 Global Drug Modeling Software Market Outlook, By Cloud Based (2021-2030) ($MN)
7 Global Drug Modeling Software Market Outlook, By Hybrid-Based (2021-2030) ($MN)
8 Global Drug Modeling Software Market Outlook, By On-Premises (2021-2030) ($MN)
9 Global Drug Modeling Software Market Outlook, By Operating System (2021-2030) ($MN)
10 Global Drug Modeling Software Market Outlook, By Windows (2021-2030) ($MN)
11 Global Drug Modeling Software Market Outlook, By Linux (2021-2030) ($MN)
12 Global Drug Modeling Software Market Outlook, By Mac Os (2021-2030) ($MN)
13 Global Drug Modeling Software Market Outlook, By Other Operating Systems (2021-2030) ($MN)
14 Global Drug Modeling Software Market Outlook, By Enterprise Size (2021-2030) ($MN)
15 Global Drug Modeling Software Market Outlook, By Large Enterprise Size (2021-2030) ($MN)
16 Global Drug Modeling Software Market Outlook, By Small & Medium Enterprise Size (2021-2030) ($MN)
17 Global Drug Modeling Software Market Outlook, By Purchasing Model (2021-2030) ($MN)
18 Global Drug Modeling Software Market Outlook, By Subscription Based (2021-2030) ($MN)
19 Global Drug Modeling Software Market Outlook, By One-Time License (2021-2030) ($MN)
20 Global Drug Modeling Software Market Outlook, By Application (2021-2030) ($MN)
21 Global Drug Modeling Software Market Outlook, By Cellular Simulation (2021-2030) ($MN)
22 Global Drug Modeling Software Market Outlook, By Cheminformatics (2021-2030) ($MN)
23 Global Drug Modeling Software Market Outlook, By Disease Modeling (2021-2030) ($MN)
24 Global Drug Modeling Software Market Outlook, By Drug Discovery and Development (2021-2030) ($MN)
25 Global Drug Modeling Software Market Outlook, By Gene Sequence Analysis (2021-2030) ($MN)
26 Global Drug Modeling Software Market Outlook, By Graphical Molecular Modeling (2021-2030) ($MN)
27 Global Drug Modeling Software Market Outlook, By Medical Imaging (2021-2030) ($MN)
28 Global Drug Modeling Software Market Outlook, By Protein Modeling (2021-2030) ($MN)
29 Global Drug Modeling Software Market Outlook, By Other Applications (2021-2030) ($MN)
30 Global Drug Modeling Software Market Outlook, By End User (2021-2030) ($MN)
31 Global Drug Modeling Software Market Outlook, By Contract Research Organizations (CROs) (2021-2030) ($MN)
32 Global Drug Modeling Software Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
33 Global Drug Modeling Software Market Outlook, By Hospitals & Healthcare Providers (2021-2030) ($MN)
34 Global Drug Modeling Software Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
